13 results about "Alveolus pulmonis" patented technology

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The invention discloses an exosome composition containing resveratrol, astragalus membranaceus and ginseng as well as a preparation method and application of the exosome composition, and belongs to the technical field of biological medicines. The exosome composition disclosed by the invention is obtained by inducing alveolar epithelial cells by active ingredients containing resveratrol, an astragalus extract and a ginseng extract and then secreting the alveolar epithelial cells. The preparation method of the exosome composition mainly comprises the following steps: co-culturing the active component and alveolar epithelial cells, and then sequentially carrying out differential centrifugation and ultracentrifugation on the collected cell supernatant to purify the exosome. The invention also provides a pharmaceutical preparation containing the exosome composition. According to the composition, traditional Chinese medicine active ingredients are combined with a modern cell exosome technology, a potential strategy is provided for prevention and treatment of pulmonary fibrosis, and the composition has a good application prospect.

The present application provides a kind of complex based on aspergillus oryzae spore, it is constituted by carbonized aspergillus oryzae spore microsphere surface and the quercetin loaded in aperture;The average porosity of the carbonized aspergillus oryzae spore microsphere is 25%~45%;The mass of the quercetin accounts for 30%‑50% of the total mass of the complex.The complex of the present application significantly improves the solubility and bioavailability of quercetin, and the optimized aerodynamic diameter ensures efficient alveolar deposition, and the rough surface ensures the rapid uptake of macrophages.In vivo and in vitro ALI model verifies the safety of the complex QU-cASP prepared by the present application and has excellent effect in targeted delivery, inhibition of oxidative stress and regulation of macrophage polarization.The present application also provides a method for preparing the complex, the application of the complex in preparing a drug for relieving acute lung injury, and an inhalable preparation with the complex as the active ingredient.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

The application discloses application of CD244 in a gene editing target point against African swine fever. The application provides application of a substance capable of inhibiting CD244 expression in preparation of a product for treating and / or preventing African swine fever virus infection. Inhibition of expression of the CD244 gene in porcine primary alveolar macrophage (PAM) can significantly interfere with ASFV replication, and overexpression of CD244 can significantly promote ASFV replication in an iPAM cell line. The application provides new materials for research and development of anti-ASFV infection drugs and pig disease-resistant breeding.

The application discloses a kind of Sargassum fusiforme low molecular weight fucoidan, and its preparation method is as follows: S1, defatting treatment;S2, preparation of crude polysaccharide;S3, degradation of crude polysaccharide: Sargassum fusiforme fucoidan crude product is dissolved into polysaccharide solution with water, H2O2 is added, and degradation is carried out under ultraviolet light, to obtain Sargassum fusiforme low molecular weight fucoidan DSFF;S4, purification: Sargassum fusiforme low molecular weight fucoidan DSFF is dissolved into polysaccharide solution with water, loaded on DEAE-52 cellulose anion exchange column and eluted with NaCl solution, the eluate is concentrated and dialyzed, and freeze-drying is obtained.The application of the Sargassum fusiforme low molecular weight fucoidan in the preparation of drugs with anti-PM2.5 lung injury effect.The Sargassum fusiforme low molecular weight fucoidan of the application has low molecular weight, is easy to absorb, and has high bioavailability.The research of the application lays a foundation for the development of Sargassum fusiforme fucoidan related lung alveolus protection products.

The present application relates to the technical field of nucleic acid detection, and discloses a general primer pair for detecting the genus of Segniliparus and application thereof. The detection primer pair and identification method provided by the present application are applicable to all species of the genus of Segniliparus, including but not limited to Segniliparus rugosus, and especially unnamed ANI species. The amplification method provided by the present application has low requirements for templates, and is applicable to clinical original samples such as sputum, alveolar lavage fluid, pleural and peritoneal fluid, culture, and environmental original samples such as water, soil and air, and extracted nucleic acid, and does not depend on culture. The method is fast and low-cost, and has low requirements for equipment and detection personnel, and is applicable to laboratories at all levels. The detection reagent based on the present application can be widely applied to related fields such as environmental monitoring, clinical precise detection and epidemiological research.

The invention discloses a pharmaceutical composition containing a pseudo-ginseng extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention provides a pharmaceutical composition containing a pseudo-ginseng extract, and tests prove that the pharmaceutical composition containing the pseudo-ginseng extract has a treatment effect on bacterial pneumonia induced by klebsiella pneumonia. Specifically, the pharmaceutical composition containing the pseudo-ginseng extract can significantly reduce the levels of IL-6, IL-1beta and TNF-alpha in alveolar lavage fluid; the mouse lung index is obviously reduced; the bacterial load in the lung tissue of the mouse is obviously reduced; the mouse lung tissue injury degree is obviously reduced; the number of neutrophils and the number of leukocytes in mouse blood are obviously reduced; the composition also has the effect of remarkably relieving increase of inflammatory factors in serum caused by klebsiella pneumoniae, and the effect is equivalent to or superior to that of a positive control drug ceftriaxone sodium. The invention provides a new choice and idea for clinical treatment of bacterial pneumonia.

The invention relates to the technical field of biology, and particularly discloses a method for inducing differentiation and maturation of alveolar organs and application of the method. The method for inducing differentiation and maturation of the alveolar organoid comprises the following steps: performing differentiation induction on the alveolar organoid in an early alveolar stage in a suspension culture manner; the suspension culture is carried out in an alveolar organ culture medium, and polydopamine nanoparticles are additionally added into the alveolar organ culture medium. In ALO in-vitro long-term culture, through combination of suspension culture and PDA NPs, AT2 differentiation efficiency in ALO is improved, AT2 function maturation is promoted, and the application effect of ALO in the fields of lung injury repair and transplantation regeneration can be improved.

This invention belongs to the field of new pharmaceutical technology and relates to a nebulized inhalation formulation for treating chronic obstructive pulmonary disease (COPD) and asthma, and its preparation method. Specifically, it relates to a nebulized inhalation solution formulation of an aminotetraphenylporphyrin photosensitizer (D4) with high light sensitivity. This invention uses an aminotetraphenylporphyrin photosensitizer (D4) as the active ingredient for treating COPD and asthma. The prepared D4 nebulized inhalation formulation comprises the following components: 200-400 μg / ml of the small molecule compound D4 solution, 0.1%-0.6% w / w acrylic polymer carbopol / 3%-25% w / w poloxamer 407 / 3%-25% w / w poloxamer 188, appropriate amounts of isotonic agent, pH adjuster, and purified water. The D4 nebulized inhalation formulation prepared by this invention, after excitation with a 650nm laser, shows significant therapeutic effects on COPD and asthma. After treatment, the alveolar septa narrowed, inflammatory infiltration decreased, airway changes were alleviated, and the thickness of the airway wall, smooth muscle layer, and basement membrane layer decreased. This method is highly effective, low in toxicity, highly targeted, has high nebulization efficiency, a short treatment cycle, and the preparation method is simple, convenient, and reliable, facilitating the establishment of quality control standards in production and promoting drug quality monitoring and large-scale production.

The invention provides preparation and application of engineered extracellular vesicles modified by SP-D protein, and belongs to the technical field of biological medicine. The invention provides engineered extracellular vesicles (SP-D-EVs) modified by utilizing pulmonary surfactant protein D (SP-D), the SP-D-EVs have the effect of actively targeting alveolar epithelium, are high in targeting property and are efficiently enriched in the lung, and a new delivery platform is provided for accurate treatment of lung diseases. The SP-D-EVs disclosed by the invention is good in expression in form, protein and surface modification detection, has good membrane integration stability, can be used for remarkably improving and treating acute lung injury, and shows anti-inflammatory and tissue repair effects. The SP-D-EVs disclosed by the invention can also be used as a universal platform and a delivery carrier, is suitable for drug delivery research of various lung diseases, and has relatively high universality and conversion value.

The application belongs to the technical field of new application of medicines, and particularly relates to hydroxycinnamic acid derivatives, a preparation method and application thereof. The ARDS model is induced by LPS tracheal instillation combined with hydroxycinnamic acid derivatives, the alveolar lavage fluid cell count is determined, and the pathological characteristics and the expression level of inflammatory genes of lung tissues are detected; the results show that the hydroxycinnamic acid derivatives can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce the expression level of inflammatory factors.

The application belongs to the technical field of medicine, and particularly relates to a Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition for regulating macrophage polarization and application thereof. The Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition is obtained by mixing Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus, adding water, heating extraction, reducing pressure concentration and drying. The composition obtained by the application can significantly reduce pro-inflammatory factors and improve anti-inflammatory factors through bidirectional regulation of alveolar macrophage polarization, and promote lung tissue repair, thereby providing a new scheme for clinical treatment of acute lung injury.